Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Archive Search

8 results
2:53 PM, Apr 17, 2018  |  BC Extra | Politics & Policy

Australia to evaluate Lilly's Lartruvo under new provisional pathway

BioCentury Extra, Oct. 19, 2016) . Lartruvo is a human IgG1 mAb targeting platelet derived growth factor
7:24 PM, Oct 06, 2014  |  BC Extra | Politics & Policy

FDA final guidance on pCR in neoadjuvant breast cancer

modern local and systemic therapy, including patients with high-grade tumors lacking estrogen, progesterone and epidermal growth factor
4:32 PM, Jun 12, 2014  |  BC Extra | Politics & Policy

Lung cancer master protocol study to start Monday

genomic profiles. FOCR previously disclosed the initial compounds to be studied: AZD4547 , a fibroblast growth factor
and an arm combining rilotumumab ( AMG 102 ), a human mAb against human hepatocyte growth factor/scatter …
5:53 PM, Nov 07, 2013  |  BC Extra | Politics & Policy

First five agents selected for lung cancer initiative

five compounds, which include rilotumumab ( AMG 102 ), a human mAb against human hepatocyte growth factor
scatter factor ( HGF/SF ) from Amgen Inc. (NASDAQ:AMGN); AZD4547 , a fibroblast growth factor receptor …
5:32 PM, Dec 19, 2012  |  BC Extra | Politics & Policy

EMA releases updated guidelines for biosimilar insulin products

for non-clinical comparative studies such as in vitro bioassays for affinity and insulin- and insulin-like growth factor
5:57 PM, May 29, 2012  |  BC Extra | Politics & Policy

FDA to accept new breast cancer endpoint

modern local and systemic therapy, including patients with high-grade tumors lacking estrogen, progesterone and epidermal growth factor
5:11 PM, Sep 09, 2011  |  BC Extra | Politics & Policy

FDA postpones anti-NGF meeting

had been scheduled for Sept. 13 to discuss safety issues possibly related to anti- nerve growth factor
5:22 PM, Jul 18, 2011  |  BC Extra | Politics & Policy

FDA committee to discuss anti-NGFs

Committee will meet on Sept. 13 to discuss safety issues possibly related to anti- nerve growth factor